Healthy Adult Participants
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Edgewise TherapeuticsEDG-7500
PfizerOral [14C] PF-07248144
mAbxiencePalivizumab
TakedaVortioxetine
Clinical Trials (4)
Total enrollment: 116 patients across 4 trials
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
Start: Mar 2026Est. completion: Jun 202624 patients
Phase 1Not Yet Recruiting
A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults
Start: Oct 2025Est. completion: Jan 20268 patients
Phase 1Completed
Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
Start: Jul 2020Est. completion: Oct 202056 patients
Phase 1Completed
A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
Start: Feb 2018Est. completion: Apr 201828 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space